Increasing advancement in the filling of formulations is expanding the prefilled syringes market size

 
The use of prefilled syringes for injection is becoming increasingly popular among physicians and healthcare providers. Prefilled syringes have many benefits over vial or penile injections: they are easier to inject, offer more consistent results, eliminate the need for a large an instrument to transfer a medication, and they do not require one person to administer the injection (which means there is a reduced risk of drug exposure or injury to staff during administration). Most prefilled syringes require the user to insert the syringe into a vial and then inject the contents of the vial into the tip of the syringe. In addition, some manufacturers have adopted the use of rubber cup lids to keep the syringe needle free from debris and to prevent injury to the fingers while pulling the plunger.

The growing prevalence of chronic disease around the globe coupled with the rising awareness regarding the benefits of the product is driving the growth of the prefilled syringes market. An increasing number of biologics and biosimilars in the pharmaceutical industry is again fueling the growth of the market. Technological advancement for developing superior quality products and filling procedures for ensuring stability in prefilled syringes is also projected to foster the growth of the prefilled syringes market. Benefits such as increased product life span and minimized drug wastage as compared to traditional methods are further anticipated to augment the growth of the prefilled syringes market.

On the other hand, complexities associated with prefilled syringes are projected to hinder the growth of the prefilled syringes market.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of diabetes which is driving demand for prefilled syringes. According to the American Diabetes Association, in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents

Key Developments:

1.      In September 2018, Hikma Pharmaceuticals PLC (Hikma, Group) the multinational pharmaceutical company, has launched a new prefilled syringe capability in the US through its affiliate, Hikma Pharmaceuticals USA Inc. The first Hikma medicine available in prefilled syringe form is Heparin Sodium Injection, USP, 5000 Units/mL.

2.      In September 2019, Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling products, has launched a new tamper-evident security concept for luer-lock syringes. It features a combination of a cap adapter and label that firmly seals prefilled syringes for reliable first opening indication.